Replimune Group, Inc.
RP1 (vusolimogene oderparepvec)
advanced melanoma
Resolved
102days ago
FDA decision · Mar 27, 2026
What's at stake
The FDA's approval decision on RP1 (vusolimogene oderparepvec) for advanced melanoma is due Mar 27, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 13h ago
“the FDA has set a PDUFA action date of March 27, 2026”